{
    "hands_on_practices": [
        {
            "introduction": "The modern understanding of Langerhans Cell Histiocytosis (LCH) is rooted in its identity as a neoplasm driven by MAPK pathway mutations, most commonly $BRAF$ V600E. Interpreting genomic sequencing reports is now a core clinical skill, requiring an understanding of how a reported variant allele frequency ($f_{VAF}$) relates to the underlying biology of the tumor. This exercise guides you through deriving the fundamental relationship between $f_{VAF}$ and the fraction of mutation-carrying cells from first principles, a crucial step in quantitatively assessing tumor burden from genetic data .",
            "id": "4861890",
            "problem": "A clinician is evaluating a patient with Langerhans cell histiocytosis, a clonal myeloid neoplasm in which constitutive activation of the Mitogen-Activated Protein Kinase (MAPK) pathway through the B-Rapidly Accelerated Fibrosarcoma (BRAF) V600E mutation drives extracellular signal-regulated kinase (ERK) phosphorylation in mutant cells. In a bulk tissue specimen, high-depth sequencing reports a BRAF V600E variant allele frequency of $0.25$. Independent histopathologic quantitation estimates the tumor purity (fraction of lesional myeloid cells among all nucleated cells in the specimen) as $0.40$. Assume a diploid genome, heterozygosity of the mutation in the cells that carry it, absence of the mutation in non-lesional cells, and that ERK is fully active in all mutant cells and inactive in all non-mutant cells.\n\nUsing only the core definitions that (i) variant allele frequency is the fraction of sequencing reads carrying the mutant allele among all allelic reads in the bulk mixture and (ii) each diploid cell contributes two alleles, derive from first principles the relationship between the observed variant allele frequency and the fraction of ERK-active cells in the specimen. Then, use the provided values to calculate the predicted fraction of ERK-active cells in the specimen as a decimal. Express your final answer as a decimal fraction. No rounding is required.",
            "solution": "The problem requires the derivation of a relationship between the variant allele frequency (VAF) of a heterozygous mutation and the fraction of cells in a sample that harbor this mutation, followed by a calculation using provided data. The core of this problem rests on a clear, first-principles definition of VAF in the context of a mixed population of cells.\n\nLet us define the relevant variables as follows:\n- $f_{VAF}$ is the variant allele frequency of the BRAF V600E mutation.\n- $f_{ERK}$ is the fraction of ERK-active cells in the specimen.\n- $f_{M}$ is the fraction of mutant cells (cells carrying the BRAF V600E mutation) among all nucleated cells.\n- $P_{T}$ is the tumor purity, defined as the fraction of lesional myeloid cells among all nucleated cells.\n- $N$ is the total number of nucleated cells in the bulk tissue specimen.\n\nThe problem makes several key statements that establish equivalences between these fractions:\n1.  \"ERK is fully active in all mutant cells and inactive in all non-mutant cells.\" This statement directly links the biological activity (ERK phosphorylation) to the genetic status (presence of the mutation). Therefore, the fraction of ERK-active cells is identical to the fraction of mutant cells:\n    $$f_{ERK} = f_{M}$$\n2.  Langerhans cell histiocytosis is described as a clonal neoplasm driven by the BRAF mutation, and tumor purity, $P_{T}$, is defined as the fraction of lesional cells. In this idealized model, the \"lesional cells\" are precisely the \"mutant cells\". Thus:\n    $$f_{M} = P_{T}$$\nCombining these, the quantity we seek to calculate, $f_{ERK}$, is the same as the fraction of mutant cells, $f_{M}$. Our task is to derive the relationship between $f_{M}$ and $f_{VAF}$.\n\nThe variant allele frequency is defined as the ratio of the number of sequencing reads carrying the mutant allele to the total number of reads covering that specific genomic locus. Assuming unbiased sequencing, this frequency is equivalent to the proportion of mutant alleles in the total pool of alleles from the cells in the sample.\n$$f_{VAF} = \\frac{\\text{Total number of mutant alleles}}{\\text{Total number of alleles}}$$\n\nWe can express the numerator and denominator in terms of $f_{M}$ and $N$.\n- The number of mutant cells is $f_{M} \\times N$.\n- The number of non-mutant (wild-type) cells is $(1 - f_{M}) \\times N$.\n\nThe total number of alleles at this locus in the sample depends on the ploidy. The problem states to assume a diploid genome, meaning each cell contains two alleles for the BRAF gene.\n- Total number of alleles = (Total number of cells) $\\times 2 = 2N$.\n\nThe total number of mutant alleles is determined by the number of mutant cells and their zygosity. The problem specifies that the mutation is heterozygous in the cells that carry it.\n- Each mutant cell contains $1$ mutant allele and $1$ wild-type allele.\n- Each non-mutant cell contains $2$ wild-type alleles and $0$ mutant alleles.\n- Therefore, the total number of mutant alleles in the sample is solely from the mutant cell population:\n  Total number of mutant alleles = (Number of mutant cells) $\\times 1 = (f_{M} \\times N) \\times 1 = f_{M}N$.\n\nNow we substitute these expressions back into the definition of $f_{VAF}$:\n$$f_{VAF} = \\frac{f_{M}N}{2N}$$\nThe total number of cells, $N$, cancels from the numerator and denominator, yielding the direct relationship between the variant allele frequency and the fraction of mutant cells:\n$$f_{VAF} = \\frac{f_{M}}{2}$$\nSince we established that $f_{ERK} = f_{M}$, the relationship between the VAF and the fraction of ERK-active cells is:\n$$f_{ERK} = 2 \\times f_{VAF}$$\nThis equation represents the relationship derived from first principles as requested.\n\nThe final step is to calculate the predicted fraction of ERK-active cells using the provided values. The problem gives the BRAF V600E variant allele frequency as $f_{VAF} = 0.25$. Applying our derived formula:\n$$f_{ERK} = 2 \\times 0.25 = 0.5$$\nTherefore, the predicted fraction of ERK-active cells in the specimen is $0.5$.\n\nIt is important to note that the problem also provides an estimated tumor purity of $P_{T} = 0.40$. Within our idealized model, this would imply $f_{ERK} = f_{M} = P_{T} = 0.40$. This value is inconsistent with the prediction of $f_{ERK} = 0.5$ derived from the VAF. Such discrepancies are common in practice and may arise from factors not included in this simplified model (e.g., aneuploidy, copy number alterations, or inaccuracies in histopathologic estimation). However, the problem specifically instructs to derive the relationship involving VAF and then use it to calculate a *predicted* value. This directs us to use the VAF as the input for our model-based calculation. The predicted fraction of ERK-active cells based on the genetic data is therefore $0.5$.",
            "answer": "$$\\boxed{0.5}$$"
        },
        {
            "introduction": "While genetic analysis reveals the driving mutation, the definitive diagnosis of LCH relies on histopathology, where immunohistochemical markers like CD1a are essential. However, the true value of a diagnostic test lies not just in its result, but in how much it shifts our clinical certainty. This practice  challenges you to move beyond sensitivity and specificity to calculate the positive likelihood ratio ($LR^{+}$), a powerful tool in evidence-based medicine that quantifies exactly how much a positive test result increases the odds of disease.",
            "id": "4861919",
            "problem": "A hematopathology consult is evaluating a suspected case of Langerhans cell histiocytosis (LCH) in an adult with lytic bone lesions. Immunohistochemistry for cluster of differentiation 1a (CD1a) is performed on the biopsy specimen. In a rigorously validated cohort, the CD1a stain has a sensitivity of $0.92$ for LCH and a specificity of $0.88$ among patients without LCH who undergo similar biopsies for mimicking conditions. Starting from the definitions of sensitivity as $P(T^{+}\\mid D^{+})$ and specificity as $P(T^{-}\\mid D^{-})$, where $T^{+}$ denotes a positive test and $D^{+}$ denotes disease present, derive the positive likelihood ratio $LR^{+}$ as a function of these conditional probabilities and compute its numerical value for this CD1a test. Then, interpret how this $LR^{+}$ would transform pretest odds into post-test odds in general terms for clinical decision-making in internal medicine. Round your numerical answer to three significant figures. Express the final numerical value without units.",
            "solution": "The first task is to derive the positive likelihood ratio ($LR^{+}$) as a function of sensitivity and specificity. The $LR^{+}$ is defined as the ratio of the probability of a positive test result in a patient with the disease to the probability of a positive test result in a patient without the disease. Mathematically, this is:\n$$\nLR^{+} = \\frac{P(T^{+} \\mid D^{+})}{P(T^{+} \\mid D^{-})}\n$$\nThe numerator, $P(T^{+} \\mid D^{+})$, is the probability of a true positive, which is the definition of sensitivity.\n$$\n\\text{Sensitivity} = P(T^{+} \\mid D^{+})\n$$\nThe denominator, $P(T^{+} \\mid D^{-})$, is the probability of a false positive. We are given the specificity, which is the probability of a true negative, $P(T^{-} \\mid D^{-})$. For an individual without the disease (condition $D^{-}$), the test can only be positive ($T^{+}$) or negative ($T^{-}$). These are mutually exclusive and exhaustive outcomes. Therefore, the sum of their probabilities is $1$.\n$$\nP(T^{+} \\mid D^{-}) + P(T^{-} \\mid D^{-}) = 1\n$$\nWe can rearrange this equation to solve for the false positive rate, $P(T^{+} \\mid D^{-})$:\n$$\nP(T^{+} \\mid D^{-}) = 1 - P(T^{-} \\mid D^{-})\n$$\nSince $P(T^{-} \\mid D^{-})$ is the definition of specificity, we have:\n$$\nP(T^{+} \\mid D^{-}) = 1 - \\text{Specificity}\n$$\nSubstituting the expressions for sensitivity and ($1-$ specificity) into the definition of $LR^{+}$, we arrive at the desired derivation:\n$$\nLR^{+} = \\frac{\\text{Sensitivity}}{1 - \\text{Specificity}}\n$$\n\nThe second task is to compute the numerical value of $LR^{+}$ for the given CD1a test. The problem provides:\n-   Sensitivity $= 0.92$\n-   Specificity $= 0.88$\n\nUsing the derived formula:\n$$\nLR^{+} = \\frac{0.92}{1 - 0.88} = \\frac{0.92}{0.12}\n$$\nThe calculation is:\n$$\nLR^{+} = \\frac{92}{12} = \\frac{23}{3} \\approx 7.666...\n$$\nRounding to three significant figures as requested gives:\n$$\nLR^{+} \\approx 7.67\n$$\n\nThe third task is to interpret how $LR^{+}$ transforms pre-test odds into post-test odds. This relationship is derived from Bayes' theorem, expressed in odds form. The odds of an event $A$ are defined as $O(A) = \\frac{P(A)}{1-P(A)}$.\n\nThe pre-test odds of disease are the odds of having the disease before the test result is known:\n$$\n\\text{Odds}_{\\text{pre}} = \\frac{P(D^{+})}{P(D^{-})}\n$$\nThe post-test odds of disease are the odds of having the disease after a positive test result ($T^{+}$) is obtained:\n$$\n\\text{Odds}_{\\text{post}} = \\frac{P(D^{+} \\mid T^{+})}{P(D^{-} \\mid T^{+})}\n$$\nUsing the definition of conditional probability, $P(A \\mid B) = \\frac{P(B \\mid A)P(A)}{P(B)}$, we can write:\n$$\nP(D^{+} \\mid T^{+}) = \\frac{P(T^{+} \\mid D^{+}) P(D^{+})}{P(T^{+})}\n$$\n$$\nP(D^{-} \\mid T^{+}) = \\frac{P(T^{+} \\mid D^{-}) P(D^{-})}{P(T^{+})}\n$$\nSubstituting these into the expression for post-test odds:\n$$\n\\text{Odds}_{\\text{post}} = \\frac{\\frac{P(T^{+} \\mid D^{+}) P(D^{+})}{P(T^{+})}}{\\frac{P(T^{+} \\mid D^{-}) P(D^{-})}{P(T^{+})}} = \\frac{P(T^{+} \\mid D^{+})}{P(T^{+} \\mid D^{-})} \\times \\frac{P(D^{+})}{P(D^{-})}\n$$\nWe recognize the first term as the definition of $LR^{+}$ and the second term as the definition of pre-test odds. This yields the fundamental relationship:\n$$\n\\text{Odds}_{\\text{post}} = LR^{+} \\times \\text{Odds}_{\\text{pre}}\n$$\n**Interpretation**: The positive likelihood ratio, $LR^{+}$, is the factor by which the pre-test odds of having a disease are multiplied to yield the post-test odds of having the disease, given a positive test result. An $LR^{+}$ greater than $1$ increases the odds (and thus the probability) that the disease is present. An $LR^{+}$ of $7.67$, as calculated for the CD1a test, indicates a moderately powerful positive test. A positive result from this test makes the diagnosis of LCH about $7.67$ times more likely than it was before the test was performed. For clinical decision-making, such a result substantially strengthens the suspicion of LCH and would typically support proceeding with a diagnosis or further confirmatory steps, depending on the initial clinical suspicion (pre-test probability).",
            "answer": "$$\n\\boxed{7.67}\n$$"
        },
        {
            "introduction": "The presence of a $BRAF$ mutation is more than a diagnostic clue; it carries significant prognostic weight, influencing patient risk stratification and management. To rigorously compare outcomes between patient groups, we must use the tools of survival analysis, such as the hazard ratio ($HR$). This problem  provides a scenario to practice converting observed relapse probabilities into their underlying constant hazard rates and calculating the $HR$, thereby quantifying the prognostic impact of the *BRAF* V600E mutation.",
            "id": "4861956",
            "problem": "In a prospective cohort of adults with Langerhans cell histiocytosis (LCH), patients are stratified by the presence of the BRAFV600E mutation. Over a follow-up horizon of $2$ years, the observed cumulative probability of first relapse by $t = 2$ years is $0.30$ in the BRAFV600E-positive group and $0.15$ in the BRAFV600E-negative group. Assume the following:\n- Within each mutation stratum, the instantaneous hazard of relapse is constant over the $2$-year interval.\n- Censoring is non-informative and competing risks are negligible over this horizon.\n- The survival function $S(t)$ and hazard function $h(t)$ satisfy the standard relationship $h(t) = - \\frac{d}{dt}\\ln S(t)$, and the cumulative incidence is $F(t) = 1 - S(t)$.\n\nUsing only these foundations, derive the group-specific constant hazards from the given $2$-year cumulative incidences, and compute the hazard ratio (HR) comparing BRAFV600E-positive to BRAFV600E-negative patients. State the hazard ratio as a single dimensionless number. Round your final answer to three significant figures.",
            "solution": "The central task is to compute the hazard ratio ($HR$) between two patient strata, defined by the presence or absence of the $BRAFV600E$ mutation. This requires first determining the constant hazard rate for each group from the provided cumulative incidence data.\n\nWe begin with the fundamental relationship between the survival function, $S(t)$, and the instantaneous hazard function, $h(t)$:\n$$h(t) = - \\frac{d}{dt}\\ln S(t)$$\nThe problem states that within each stratum, the hazard of relapse is constant over the $2$-year interval. Let this constant hazard be denoted by $h$. The equation becomes:\n$$h = - \\frac{d}{dt}\\ln S(t)$$\nTo find the survival function $S(t)$, we integrate this ordinary differential equation with respect to time from $\\tau=0$ to $\\tau=t$:\n$$\\int_{0}^{t} h \\,d\\tau = \\int_{0}^{t} - \\frac{d}{d\\tau}\\ln S(\\tau) \\,d\\tau$$\nThe left side evaluates to $ht$. The right side, by the fundamental theorem of calculus, is:\n$$ht = -[\\ln S(\\tau)]_{0}^{t} = -(\\ln S(t) - \\ln S(0))$$\nAt time $t=0$, no events (relapses) have occurred, so the probability of survival is $S(0) = 1$. Since $\\ln(1) = 0$, the equation simplifies to:\n$$ht = -\\ln S(t)$$\nSolving for the survival function $S(t)$ by exponentiating both sides yields:\n$$S(t) = \\exp(-ht)$$\nThis is the survival function for a process with a constant hazard, which corresponds to an exponential distribution of event times.\n\nThe problem provides the cumulative probability of relapse, which is the cumulative incidence function, $F(t)$. The relationship between $F(t)$ and $S(t)$ is given as:\n$$F(t) = 1 - S(t)$$\nSubstituting the expression for $S(t)$, we have:\n$$F(t) = 1 - \\exp(-ht)$$\nWe can now solve for the constant hazard $h$ in terms of the cumulative incidence $F(t)$ at a specific time $t$:\n$$\\exp(-ht) = 1 - F(t)$$\n$$-ht = \\ln(1 - F(t))$$\n$$h = -\\frac{1}{t} \\ln(1 - F(t))$$\nThis formula allows us to calculate the group-specific constant hazards from the given data. Let $h_{pos}$ be the hazard for the $BRAFV600E$-positive group and $h_{neg}$ for the $BRAFV600E$-negative group. The follow-up horizon is $t = 2$ years.\n\nFor the $BRAFV600E$-positive group, the cumulative incidence of relapse at $2$ years is $F_{pos}(2) = 0.30$. The constant hazard is:\n$$h_{pos} = -\\frac{1}{2} \\ln(1 - 0.30) = -\\frac{1}{2} \\ln(0.70)$$\n\nFor the $BRAFV600E$-negative group, the cumulative incidence of relapse at $2$ years is $F_{neg}(2) = 0.15$. The constant hazard is:\n$$h_{neg} = -\\frac{1}{2} \\ln(1 - 0.15) = -\\frac{1}{2} \\ln(0.85)$$\n\nThe hazard ratio ($HR$) is defined as the ratio of the hazard in the exposed group (here, $BRAFV600E$-positive) to the hazard in the unexposed group ($BRAFV600E$-negative).\n$$HR = \\frac{h_{pos}}{h_{neg}}$$\nSubstituting the expressions for $h_{pos}$ and $h_{neg}$:\n$$HR = \\frac{-\\frac{1}{2} \\ln(0.70)}{-\\frac{1}{2} \\ln(0.85)}$$\nThe term $-\\frac{1}{2}$ cancels from the numerator and denominator:\n$$HR = \\frac{\\ln(0.70)}{\\ln(0.85)}$$\nWe now compute the numerical value:\n$$HR \\approx \\frac{-0.35667494}{-0.16251893} \\approx 2.19464$$\nThe problem requires the answer to be rounded to three significant figures.\n$$HR \\approx 2.19$$\nThe hazard ratio is a dimensionless number.",
            "answer": "$$\\boxed{2.19}$$"
        }
    ]
}